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Abstract: 
 Freeman-Sheldon Syndrome (FSS) is a distal arthrogryposis syndrome causing muscle 
contractures of the hands, feet, and face, as well as a small oral opening and an H-shaped 
dimpling of the chin. In addition, complications such as severe scoliosis, strabismus, and hearing 
loss are often present in patients. The syndrome has been linked to mutations in the embryonic 
myosin heavy chain gene (Myh3), which encodes the first molecular motor to be expressed 
during development. However, while the genetic basis of the disease is known, the mechanism 
by which mutations in Myh3 lead to the physical symptoms of FSS is poorly understood. Here 
the generation of an inducible skeletal muscle cell system that allows for precise studies of 
embryonic myosin’s role in developing sarcomeres is described. Using this system, it will be 
possible to gain a better understanding of the pathogenesis of FSS as caused by mutant 
embryonic myosin in developing skeletal muscle. 
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Introduction: 
I. Freeman-Sheldon Syndrome and Embryonic Myosin 
 Freeman-Sheldon Syndrome (FSS) is a severe congenital skeletal muscle syndrome 
whose mechanism of pathogenesis is currently poorly understood. FSS belongs to the distal 
arthrogryposis syndromes, and is known specifically as type DA2A (Bamshad et al., 2009). The 
disease causes muscle contractures of the hands (camptodactyly), feet (clubfeet or talipes 
equinovarus), and parts of the face, a small oral opening (microstomia), and an H-shaped 
dimpling of the chin (Figure 1). In addition to these classical characteristics of FSS, 85% of 
patients have severe scoliosis, 42% have strabismus, and 30% have hearing loss (Stevenson et 
al., 2006). FSS has been recognized as the most severe distal arthrogryposis syndrome due to the 
many complications associated with it, and is most typically passed on in a familial dominant 
pattern (Toydemir et al., 2006). However, cases of recessive inheritance have also been recorded 
(Alves and Azevedo, 1977; Wang et al., 1987) as well as de novo cases (Sánchez et al., 1986; 
Toydemir et al., 2006). 
 
 
 
 
Figure 1: A father and son with classical FSS characteristics. The H-shaped 
dimpling of the chin and microstomia, as well as the camptodactyly can be seen 
(Stevenson et al., 2006). 
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Mutations in the embryonic myosin heavy chain gene (Myh3) have been strongly 
implicated in this syndrome. Myosins are the motor proteins involved in muscle contraction, and 
work in a subunit of the muscle known as the sarcomere. Myosins are the most abundant protein 
in the sarcomere, and they are essential for muscle contraction. ATP binds myosins and is used 
as an energy source for the movement of the myosins along actin filaments in the sarcomere 
during muscle contraction. Embryonic myosin is one of three myosin isoforms expressed during 
fetal development (Lu et al., 1999) (Figure 2). Expression of embryonic myosin is turned off 
shortly after birth, and is reactivated during adult muscle regeneration. During development, 
embryonic myosin is expressed throughout the skeletal muscle of embryos (Lu et al., 1999). It 
has also been shown that embryonic myosin is expressed in the developing heart of chicks 
(Rutland et al., 2011). Embryonic myosin is part of a gene cluster that also contains the IIa, IIb, 
IId/x, extraocular, and perinatal myosin genes. 
 
 
 
 
 
Figure 2: Expression profile of six myosin isoforms in mouse embryos. It can be 
seen that embryonic myosin (denoted “Emb”) is highly expressed on day 15 of 
fetal development, and its expression decreases by day 19. “dpc” denotes days 
post-coitum (Lu et al., 1999). 
Kokkonen	   6	  
Several point mutations in the Myh3 gene resulting in single amino acid changes have 
been directly linked to FSS (Toydemir et al., 2006).  The mechanism by which mutations in 
Myh3 lead to the physical symptoms of FSS is not fully understood. However, most of these 
mutations are located near the ATP-binding pocket in the motor domain of embryonic myosin 
(Figure 3), which implies that the mutations interfere with ATP binding, hence decreasing the 
effectiveness of embryonic myosin during fetal muscle contraction. 
  
 
 
 
The most common of the point mutations in Myh3 that have been linked to FSS are 
R672C and R672H. These two mutations account for approximately 72% of FSS cases 
(Toydemir et al., 2006). Both these mutations are located at the same amino acid position, 
indicating this is a mutational hot spot in the Myh3 gene. Given the high frequency of these two 
Figure 3: Protein structure of embryonic myosin. Mutations causing FSS are 
denoted in red. (Toydemir et al., 2006) 
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mutations within the FSS population, this project has concentrated on these two mutants in order 
to help understand the pathogenesis of FSS. 
To date, little in-depth research has been performed on mutations in Myh3 that are 
associated with FSS.  The majority of studies done concerning FSS have been case studies of 
patients, which detail physical symptoms associated with the syndrome (Stevenson et al., 2006). 
Immunohistochemical staining of patient muscle biopsies has been rare, and often is done with 
samples from muscles that are either not affected or only weakly affected by FSS. One larger 
study by Toydemir et al. involving 28 patients was performed which led to more detailed 
analysis of the mutations in Myh3 that lead to FSS. In this study, the most common FSS-causing 
mutations in Myh3 were determined, as well as their relative locations in the embryonic myosin 
protein. This study has been the only large genetic screen of FSS patients done to date, and has 
been highly influential as it was the first study to map the mutations in Freeman-Sheldon patients 
to the embryonic myosin heavy chain gene (Toydemir et al., 2006).  
Currently, the only treatment options for FSS patients are postnatal corrective surgeries 
on the affected distal limbs. However, these surgeries are often complicated, with multiple 
operations being necessary in order to fully correct the muscle contractures. FSS patients 
frequently have an increased sensitivity to anesthesia (Laishley and Roy, 1986) making 
operations more risky than for normal patients. Due to this and the various other complications 
of living with FSS, insight into the mechanisms of FSS could be invaluable for producing better 
therapies for this syndrome in the future, as well as gaining a general knowledge of the role of 
embryonic myosin in human disease.  
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II. The Cell System 
 This project involved the generation of a unique cell system via integration of a reporter 
gene cassette into the genome of cells using a retrovirus. The reporter gene cassette contains the 
luciferase and GFP genes, which allow for screening of cells both by biochemical luminescence 
and fluorescence. These two genes are under the control of Tet-On promoter. The salient feature 
of the cell system is the ability to replace the stably integrated reporter gene cassette with a 
cassette containing a gene of interest (in this case, the embryonic myosin heavy chain gene, 
Myh3). This cassette exchange is mediated by Flp-recombinase, and so is known as recombinase 
mediated cassette exchange (RMCE) (Schlake and Bode, 1994). In order to use Flp-recombinase 
to mediate cassette exchange, the cassette includes two unique Flp recombination target (FRT) 
sites at the ends (Figure 4). This allows for direction-specific insertion of cassettes. 
             
 
 
Figure 4: Diagram of recombinase-mediated cassette exchange (RMCE) in the 
C2C12 cell line. The luc/GFP reporter gene cassette is shown being exchanged for 
the luc/Myh3 cassette. The two different purple triangles represent the two 
different FRT sites flanking the cassette, with light purple being wild-type FRT 
and dark purple being the variant FRT3. 
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 The cell system also features the Tet-On promoter, which allows for fine-tuned control of 
gene expression from the cassette. The Tet-On promoter is controlled by the addition of 
doxycycline (dox). When dox is added, the rtTA transactivator binds to the Tet-On promoter to 
induce expression (Gossen and Bujard, 1992) (Figure 5A and B). The Tet-On promoter used in 
this system is bi-directional, which allows for expression of both the gene of interest and a 
reporter gene, such as luciferase. Being able to induce expression from the Tet-On promoter, 
along with the ability to use RMCE to insert cassettes containing genes of interest, makes this 
cell system an ideal way of studying FSS at the sarcomere level of skeletal muscle. 
         
 
 
 
 
 The specific cell lines generated in this project were derived from the C2C12 mouse 
skeletal muscle cell line. These cells can be differentiated from myoblasts into myotubes, which 
allows for studies of sarcomere structure and function without the use of a model organism. The 
cell lines are derived from a isogenic population of cells, making expression from the integrated 
Figure 5: Diagram of how the Tet-On promoter works. A) In the absence of dox, the 
Tet-On promoter is not active, and gene expression does not occur (indicated by the 
red “X”). B) In the presence of dox, the transactivator rtTA activates the Tet-On 
promoter, and gene expression occurs. 
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cassette uniform throughout the cell population. This eliminates any uncertainty in results due to 
variation between different cells in their expression profiles, as all cell lines have identical 
integration sites of the cassette in the genome. The integrated cassette contains the luciferase 
gene, as well as the mutant or wild-type Myh3 gene. The Myh3 gene has an added Myc tag to 
allow for the transgene embryonic myosin to be distinguished from the endogenous myosins in 
the cells. 
 Ultimately this cell system comprises only one part of the approach towards investigating 
embryonic myosin’s role in FSS, as cell culture cannot address the physiological role of 
embryonic myosin in an organism. In order to address this, transgenic mouse lines have been 
generated to facilitate studies of FSS in the setting of a model organism. The mice provide an in 
vivo approach for elucidating the mechanism of FSS, while the cell system model provides an in 
vitro look at the disease. Additionally, biochemical assays are being performed to further 
understand the behavior of embryonic myosin, both in its wild-type and mutant forms. In this 
thesis, however, the discussion will be limited to development and studies of the in vitro cell 
system. 
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Materials and Methods: 
Overview of Cell System Generation 
 The following flowchart provides an overview of the process of generating the cell 
system as well as the studies done at each step (Figure 6). Detailed methods for the entire process 
follow this overview. 
 
 
 
 
 
Cell Culture 
 For normal growth, C2C12 myoblasts were cultured in DMEM (Dulbecco’s Modified 
Eagle Medium, Invitrogen) containing 20% FBS, 100U penicillin/streptomycin, 4 mM L-
glutamine, and 1 mM sodium pyruvate (overall, referred to as “growth media”). For 
differentiation, C2C12 myotubes were cultured in DMEM containing 2% horse serum, 100U 
penicillin/streptomycin, 4 mM L-glutamine, and 1 mM sodium pyruvate (overall, referred to as 
“differentiation media”). 
Figure 6: A flowchart overview of the generation of the cell system. Black arrows 
represent major procedural steps; blue arrows represent studies done to 
characterize the indicated cell lines. 
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 During retroviral transduction, HEK293T cells were cultured in DMEM containing 10% 
heat-inactivated FBS, 100U penicillin/streptomycin, 4 mM L-glutamine, and 1 mM sodium 
pyruvate. 
 All cells were kept in incubators set to 37° C and 5% CO2. 
Plasmid Constructs 
 The constructs pVPack-vsvg, pVPack-gagpol, SF2cLM2CGFRT3, pCAGGS-Flpe-IRES-
Puro, and pMefc2Myo-mouseMyh3 (WT, RC, or RH) were graciously provided by Ina 
Weidenfeld. The constructs SF2-luc/Myh3 (WT, R672C, or R672H) FRT3 were derived from 
the parent construct SF2cLM2CgFRT3 via EcoRI/NotI digestion to remove the GFP gene. A 
multiple cloning site containing the restriction sites AgeI and MluI was ligated into the resulting 
plasmid via EcoRI and NotI overhangs, and reopened via AgeI/MluI digestion. The Myh3 gene 
(either WT, R672C, or R672H) was then ligated into the gap. The Myh3 gene was derived from 
the parent construct pMef-Myog-Myh3 (WT, RC, or RH) via AgeI/MluI digestion. Sequencing 
to verify correct gene sequence was performed by ACGT, Inc. with primers that covered the 
entire Myh3 gene sequence. 
 Plasmid maps, the multiple cloning site sequence, and primer sequences can be found in 
the Supplementary Materials. 
C2C12 Reporter Cell Line Generation 
 HEK293T cells were cultured in DMEM media containing 10% heat-inactivated FBS. 
FBS was inactivated at 55° C. Virus production was carried out according to the protocol in 
Loew et al., 2006. The construct SF2cLM2CGFRT3 was co-transfected along with the viral 
packaging vectors pVPack-gagpol  and pVPack-vsvg. A previously generated C2C12 cell line 
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constitutively expressing the rtTA gene, designated clone #18, was infected with the resulting 
retrovirus. 
 Infected C2C12 cells were then induced with 200 ng/mL doxycycline (dox) for 16 hours. 
Cells were sorted via FACS (fluorescence-activated cell sorting) four times, with the first sort 
selecting for cells that responded to addition of dox by expressing GFP from the reporter 
cassette, the second and third sorts selecting for cells that did not express from the reporter 
cassette in the absence of dox, and the fourth sort again selecting for cells that responded to the 
addition of dox. These four rounds of sorting were used in order to isolate cells with a low 
expression level from the cassette in the absence of dox, but with a high expression level in the 
presence of dox. 
 Following these FACS of C2C12 populations, C2C12 cells were then sorted as single cells 
following 16-hour induction with 200 ng/mL of dox. Single cells were placed in 96-well plates. 
Luciferase assays to determine amount of induction with dox were then performed on the single 
cell clones according to Promega protocol, with a non-induced sample as a control, and a dox-
induced sample for analysis. Induced samples were induced with 500 ng/mL dox for 24 hours. 
Differentiation capabilities of single cell clones were also tested by seeding cells on gelatin-
coated coverslips in C2C12 differentiation media and observing myotube and sarcomere 
formation. Differentiation proceeded for 12 days, with induced samples being induced with 500 
ng/mL dox. The differentiation media was changed daily. Immunofluorescence staining was 
carried out according to the protocol in Weidenfeld et al., 2009. Antibodies used were mouse 
F59 IgG1 directed against myosin head groups (Leinwand lab) and goat anti-mouse Alexa Fluor 
568 IgG1 (Invitrogen). Imaging of samples was performed on a Nikon A1R confocal 
microscope. 
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 After luciferase assays and differentiation studies, clone 18-8 luc/GFP was chosen for 
further studies due to its high level of induction upon addition of dox and its ability to 
differentiate into myotubes containing sarcomeres.  
 
C2C12 luc/Myh3 Cell Line Generation from Reporter Cell Line 18-8 luc/GFP 
 C2C12 reporter cell line 18-8 luc/GFP was transfected with pCAGGS-Flpe-IRESpuro and 
SF2-Myh3 luc/Myh3 (WT, R672C, or R672H) FRT3 according to Lipofectamine 2000 protocol 
(Invitrogen). Following 6 hours of transfection, a round of antibiotic selection was carried out 
with 5 µg/mL puromycin added to the normal growth media. Cells were then induced with 500 
ng/mL dox for 48 hours and sorted via FACS. Cells chosen for sorting had low fluorescence, 
indicating the exchange of the luc/GFP cassette for the luc/Myh3 cassette. Two subsequent sorts 
were carried out using the same conditions to eliminate as many cells containing the luc/GFP 
cassette as possible. 
 Cassette exchange was confirmed by isolating genomic DNA using the Qiagen DNeasy 
Blood-and-Tissue kit, and performing PCR with primers for the luc/GFP cassette and primers for 
the luc/Myh3 cassette. Control primers for the rtTA transactivator were also included. All primer 
sequences and PCR cycles can be found in the Supplementary Materials. Primers were ordered 
from Invitrogen. 
 
Differentiation Studies of C2C12 luc/Myh3 Cell Lines 
 Cells were seeded onto gelatin-coated coverslips and allowed to reach 100% confluence 
in C2C12 growth media. Growth media was then exchanged for differentiation media (day 0 of 
differentiation), and cells were allowed to differentiate for 14 days. Differentiation media was 
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changed daily. Samples were induced with 500 ng/mL dox for varying amounts of time, with one 
non-induced control per experiment. 
 Following differentiation, cells were fixed and stained according to the protocol in 
Weidenfeld et al. 2009. Antibodies used were mouse 9B11 IgG2a directed against the Myc tag of 
the transgenic embryonic myosin (Cell Signaling Technology), mouse F59 IgG1 supernatant 
directed against endogenous myosin head groups (Leinwand lab), goat anti-mouse Alexa Fluor 
647 IgG2a (Invitrogen), and goat anti-mouse Alexa Fluor 568 IgG1 (Invitrogen). Imaging of 
immunofluorescence samples was performed on a Nikon A1R confocal microscope. 
 
 
Results: 
 
1. Generation of the C2C12 Reporter Cell Line 
 
 In order to generate the reporter cell line, C2C12 cells were transduced using a retrovirus 
containing the reporter gene cassette, SF2cLM2CG-FRT3. The reporter gene cassette contains 
the luciferase and GFP genes under the control of the Tet-On promoter. Cells that stably 
integrate the reporter gene cassette into their genomes will respond to the addition of dox, 
therefore expressing luciferase and GFP. The expression of these two proteins allows for 
selection of cells that have integrated the cassette, as well as quantification of the amount of 
induction upon addition of dox. Selection of cells can be carried out by FACS, which monitors 
the fluorescence of the cells due to the GFP expressed from the reporter gene cassette. 
Quantification of induction amount can be calculated from luciferase assay data, which measures 
the light produced from the reaction of luciferase with its substrate, luciferin. 
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1.1 – Isolation of single dox-responsive cells using FACS 
Four rounds of FACS were performed following viral transduction of C2C12 cells (Figure 
7). For each round, a non-induced control, as well as a non-infected control was included. Data 
shown are for rtTA clone #18. Induced samples were induced with 200 ng/mL dox 16 hours 
prior to sorting. The first round was an “on” sort, in which cells that responded to the addition of 
dox were sorted out. The second and third rounds were “off” sorts, in which cells that did not 
express from the reporter gene cassette in the absence of dox were sorted out. The fourth sort 
was an additional “on” sort. These four sorts allowed for the selection of cells that did not 
express from the cassette in the absence of dox, and did express in high amounts in the presence 
of dox. 
Following the fourth FACS sort, single cells were then sorted into 96-well plates. 
Luciferase assays were performed for these clones to determine which had the highest level of 
inducibility (Figure 8 and Table 1). From these assays, it was determined that clone 18-8 had a 
high level of inducibility. Differentiation tests were then performed to determine whether or not 
the clones were still capable of fusing to form myotubes with sarcomeres (Figure 9). Testing 
differentiation is critical because sarcomeres are necessary in order to study the behavior of 
embryonic myosin as it occurs in developing skeletal muscle. After differentiation tests, it was 
determined that clone 18-8 still differentiated to form myotubes with sarcomeres. 
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Figure 7: Four rounds of FACS were performed on rtTA clone #18. Non-induced and 
induced samples were included for all rounds, as well as a non-transduced control (WT). 
Induced samples were induced for 16 hours with 200 ng/mL dox. Cells that were sorted 
for each round are boxed in red. Data provided courtesy of Ina Weidenfeld. 
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1.2 - Quantification of expression in single C2C12 clones using luciferase assays 
 
 
 
 #18 luc/GFP Clones 
1 2 3 4 5 6 7 8 9 10 12 16 
Fold 
Induction 
3259 240 2882 443 219 1493 1848 2862 1235 3113 1905 8030 
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Figure 8: C2C12 luc/GFP clones of #18 tested via luciferase assay. Blue indicates a non-induced 
sample, and red indicates an induced sample. Samples were induced with 500 ng/mL dox 24 hours 
prior to collection for the luciferase assay. Data provided courtesy of Ina Weidenfeld. 
Table 1: Fold induction of C2C12 luc/GFP clones of #18. The fold induction was 
calculated from luciferase assay data shown in Figure 8, and is the fold induction from 
non-induced to induced. Data provided courtesy of Ina Weidenfeld. 
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1.3 - Differentiation tests of clone 18-8 luc/GFP 
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 Following confirmation of the differentiation capabilities of clone 18-8 luc/GFP, 
recombinase-mediated cassette exchange was performed in order to exchange the luc/GFP 
reporter cassette for a luc/Myh3 cassette. Cells were isolated via FACS by looking for the loss of 
fluorescence and sorting out those cells, as this indicates the loss of the luc/GFP reporter gene 
cassette and the gain of the luc/Myh3 cassette. The luc/Myh3 R672H cell line went through three 
Figure 9: Clone 18-8 luc/GFP after 12 days of myotube differentiation. Immunofluorescence staining 
was performed for myosin head groups (F59 antibody), and cell nuclei (DAPI antibody). GFP was 
expressed directly from the reporter gene cassette. The banding pattern of F59 indicates the presence 
of sarcomeres. Induced samples were induced with 500 ng/mL dox for all 12 days. The +dox sample 
was imaged at 60X, and –dox at 100X. Data provided courtesy of Ina Weidenfeld. 
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Figure 10: PCR verification of cassette exchange in clone 18-8. Primers amplified either the 
luc/GFP cassette, the luc/Myh3 cassette, or amplified the rtTA transactivator as a control. 
Genomic DNA samples tested were reporter cell line 18-8 luc/GFP and 18-8 luc/Myh3 R672H. A 
1 kb+ ladder was used as a size marker for the gel. 
rounds of FACS in order to eliminate as many luc/GFP reporter cassette-positive cells as 
possible. Cassette exchange was verified via PCR on genomic DNA samples (Figure 10).  
 It should be noted that in the 18-8 luc/Myh3 R672H genomic DNA sample, the luc/GFP 
reporter cassette is still amplified during PCR. Given that the isolated cell lines were not 
fluorescent during both FACS and fluorescence microscopy, this indicates the presence of 
additional cassettes in the genome that are silent and cannot be exchanged via RMCE. These 
additional cassettes are likely due to the use of too much virus during the initial transduction of 
the C2C12 cells to generate the reporter cell line. 
 
2. - Verification of cassette exchange of luc/GFP for luc/Myh3 in reporter cell line 18-8 
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3. - Localization of Mutant R672H Embryonic Myosin in C2C12 Sarcomeres 
 Once cassette exchange was confirmed, differentiation studies began to determine how 
the mutant R672H embryonic myosin behaves in the sarcomeres of C2C12 myotubes. Data 
currently have only been generated concerning the localization of the mutant R672H protein in 
the sarcomeres. In order to assess where the mutant R672H protein localizes in the sarcomere, 
cells were differentiated into myotubes for 14 days. Immunofluorescence staining was then done 
to detect both endogenous myosins as well as the Myc-tagged mutant embryonic myosin in the 
sarcomeres of the differentiated cells (Figure 11). By staining for both of these, comparisons 
could be made between the normal localization of myosin versus the localization of the mutant 
embryonic myosin in sarcomeres. 
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Figure 11: Immunofluorescence of cell line 18-8 luc/Myh3 R672H after 14 days of 
myotube differentiation. F59 antibody stains for endogenous myosin head groups, 
while Myc stains for the mutant embryonic myosin expressed from the integrated 
cassette. Sarcomeres can be seen, which appear as striated bands running through the 
cells. Samples for these images were induced for either all 14 days of differentiation, 
or for days 7-14 of differentiation with 500 ng/mL dox. Samples imaged at 100X. 
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Discussion: 
 The C2C12 inducible cell system provides many advantages to investigating the 
pathogenesis of Freeman-Sheldon Syndrome. The wild-type or mutant embryonic myosin heavy 
chain gene can be directly integrated into the genome of C2C12 cells, producing stable cell lines 
with a known integration site. The system then allows for fine-tuned control over expression of 
the Myc-tagged embryonic myosin protein during myotube and sarcomere formation, which is 
critical for both localization studies and future studies of protein turnover in the sarcomeres. In 
addition, this system eliminates uncertainties in data due to different cell populations, as all cell 
lines generated from the reporter cell line are known to have identical genomic integration sites 
of the cassette. Due to this, the luc/Myh3 cell lines that are generated can be directly compared to 
one another. 
 However, the system does currently pose some concerns. Foremost among these is the 
question of whether or not the system will eventually silence the integrated transgene. In data not 
provided here, it was seen that after several rounds of RMCE the system was no longer 
responding to dox. Due to this effect, the methods used for generating the luc/Myh3 cell lines 
were modified so that RMCE was carried out directly on the reporter cell line 18-8 luc/GFP. 
Currently this silencing effect does not pose a problem, but it must be considered if the cell lines 
are to be kept in culture for long periods of time. A second concern is the multiple integration 
sites of reporter cell line 18-8 luc/GFP. Although data have shown that the additional loci are 
silent and cannot be recombined, it is possible that they still interfere slightly with the 
functioning of the cell system. The only way to remediate this issue would be to regenerate the 
original reporter cell line by performing viral transduction with less virus. 
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At this stage, data suggest that mutant R672H embryonic myosin enters and localizes in 
the sarcomere normally (Figure 11). This finding fits with the patient profile – their muscles still 
develop, indicating that embryonic myosin is able to integrate into the sarcomeres of the 
developing skeletal muscle, but the function of the embryonic myosin is somehow compromised, 
leading to contractures.  
Moving forward, there are many experiments yet to do in order to elucidate the 
mechanisms of FSS. The R672C Myh3 mutant and WT Myh3 cell lines must first be created. 
The localization of embryonic myosin will then need to be investigated in both the WT Myh3 
and R672C Myh3 cell lines to complement the data presented here for the R672H Myh3 mutant 
cell line. In addition to examining the localization of the mutant embryonic myosin, protein 
turnover in the sarcomeres will be studied to determine if turnover occurs differently in WT 
versus mutant Myh3 cell lines. These studies will be done by inducing the Myh3 cell lines for 
several days at the beginning of differentiation and then removing the dox from the 
differentiation media. Samples will be collected daily for immunofluorescence staining 
following removal of dox. The amount of Myc-tagged embryonic myosin can then be quantized 
using confocal microscopy to see at what rate embryonic myosin is being degraded in the 
sarcomeres. Third, investigations of force production in the Myh3 mutant cell lines versus the 
WT Myh3 cell line will be performed. These studies will be performed according to the protocol 
in Khodabukus and Baar, 2009 using 3D tissue engineered constructs created from the Myh3 cell 
lines. This will give insight into how the muscles of FSS patients function, and may additionally 
provide insight into the mechanism leading to the muscle contractures in FSS patients. 
Along with working with the current version of the luc/Myh3 cell lines, cloning is 
underway in order to make the isolation of the Myh3 cell lines more efficient. The luciferase 
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gene in the cassette will be replaced with the mCherry gene linked to a puromycin selection 
marker. This replacement will allow for isolation of Myh3 cell lines both by antibiotic selection 
with puromycin and by FACS by looking for the switch from green fluorescence to red 
fluorescence. Currently, antibiotic selection is not possible following RMCE of the luc/GFP 
reporter gene cassette for the luc/Myh3 cassette because both cassettes contain antibiotic-
resistance markers for gancyclovir. Following successful cloning of this new mCherry-
puro/Myh3 construct, new Myh3 cell lines will be generated by using both antibiotic selection 
and FACS. 
In addition to future studies conducted in the cell system, experimentation will be 
performed in the transgenic mouse lines to look at the spatial and temporal expression of the 
mutant embryonic myosin. Phenotyping of mice will be performed in order to understand 
differences between the function of skeletal muscles in transgenic and wild-type animals. Force 
generation could be investigated by using an ex vivo approach on muscles isolated from 
transgenic or wild-type animals. These studies would complement the work done in the cell 
system. 
 
Conclusions: 
 While the C2C12 inducible cell system does not provide a perfect method of investigation 
for fully determining the role of embryonic myosin in the pathogenesis of Freeman-Sheldon 
Syndrome, it does allow for determination of embryonic myosin’s location and role in the 
sarcomeres of differentiating skeletal muscle cells. It has been shown here that the R672H 
mutant embryonic myosin enters and localizes in the sarcomere normally, but it remains to be 
seen how it is functioning once within the sarcomere. To this end, further experimentation will 
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be performed in order to elucidate how force generation and rate of myosin turnover in 
sarcomeres differs between wild-type and mutant-carrying Myh3 lines of the C2C12 system. 
Ultimately, this work will lead to a better understanding of embryonic myosin’s role in human 
disease. More specifically, there may be future applications for potential therapies for FSS, as 
understanding the pathogenesis of the disease is crucial for the design of therapeutics. 
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Supplementary Materials: 
 
I. Plasmid Maps 
 
 SF2cLM2CG-FRT3 (reporter gene luc/GFP cassette) 
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pCAGGS-Flpe-IRES-Puro (Flp recombinase) 
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pMef2cMyo-Myh3mouse (wt, RC, or RH) (Myh3 Myc-tagged gene) 
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SF2-mouseMyh3wtluc-FRT3 (luc/Myh3 cassette) 
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II. Primer Sequences 
 
Primer Sequences for Verification of Cassette Exchange 
 
FP luc/GFP: 5’-CACCTGCGTCGAAGATGTTGGGGTGTTGGA-3’ 
 
RP luc/GFP: 5’-ACGCTGAACTTGTGGCCGTTTACGTC-3’ 
 
FP luc/Myh3: 5’-CACCTGCGTCGAAGATGTTGGGGTGTTGGA-3’ 
 
RP luc/Myh3: 5’-ACAGTGACACAGAAGAGGCCTGAA-3’ 
 
FP rtTA: 5’-CCATGTCTAGACTGGACAAGA-3’ 
 
RP rtTA: 5’-CTCCAGGCCACATATGATTAG-3’ 
 
 
Primer Sequences for Sequencing of luc/Myh3 Plasmids 
 
 FP 259: 5’-TTAAGCCAGAGGACGTGTATGCCA-3’ 
 
 RP 421: 5’-ACAGTGACACAGAAGAGGCCTGAA-3’ 
 
 FP 655: 5’-ACCTTGCCAAGAAGAAGGACTCCA-3’ 
 
 FP 1312: 5’-ATGCTGTGAACGCTCTCTCCAAGT-3’ 
 
 FP 1936: 5’-ACGGTGGGAAGAAGAAAGTCGCTA-3’ 
 
 FP 2582: 5’-TGAGAAGGAGATGGCCACCATGAA-3’ 
 
 FP 3336: 5’-GAGCAGACCTTGAGCCTCCA-3’ 
 
 FP 3938: 5’-TGTATCTCAGCTCTCCAGGA-3’ 
 
 FP 4540: 5’-TGAAACGGGAGAATAAGAAC-3’ 
 
 FP 5142: 5’-CGGAAGCTGGCAGAGCAGGA-3’ 
 
 FP 5744: 5’-CCAGCATGAGCTAGAGGAGG-3’ 
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III. Multiple Cloning Site Sequence 
 
 5’ - AATTCACCGGTTTAATTAAGGCCGGCCACGCGTTACGTAGC – 3’    
                        3’- GTGGCCAAATTAATTCCGGCCGGTGCGCAATGCATCGCCGG – 5’ 
 
 5’ - EcoRI	  -­‐	  AgeI	  –	  PacI	  -­‐	  	  	  FseI	  	  –	  MluI	  –	  SnaBI-­‐	  NotI	  –	  3’ 
 
IV. PCR Conditions for Genomic DNA PCR 
          Temp.  Time 
98° 2’ 
98° 30” 
58° 30” 
68° 2’ 30”  
 
98° 30” 
63° 40” 
68° 2’ 30” 
68° 8’ 
5X 
25X 
